Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Idelalisib: Phase II data

Data from 64 patients aged 65 and older with previously untreated CLL and SLL in the open-label, U.S. Phase II Study 101-08 showed that twice-daily 150 mg oral idelalisib plus

Read the full 307 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE